New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
February 23, 2015
10:11 EDTAAPLApple breakout continues, levels to watch
Subscribe for More Information
09:39 EDTAAPL, GOOGActive equity options trading on open
Subscribe for More Information
09:39 EDTGOOGYouTube confirms launch of kids app
Google's (GOOG, GOOGL) YouTube confirmed its launch of the YouTube Kids app, "the first Google product built from the ground up with little ones in mind," which the company said makes it safer and easier for children to find videos on topics they want to explore. The app is now available for free on Google Play and the App Store in the U.S. Reference Link
09:04 EDTAAPLApple volatility flat as shares near record
Subscribe for More Information
09:02 EDTBBRYVerizon to sell BlackBerry Classic for $100, CrackBerry says
Subscribe for More Information
08:24 EDTGOOGGoogle Vietnam site disrupted by hackers, WSJ says
Subscribe for More Information
08:03 EDTGMCRKeurig Green Mountain announces repurchase of shares held by Lavazza
Subscribe for More Information
07:29 EDTAAPLJapan Display asking Apple to finance new smartphone screen plant, Reuters says
Subscribe for More Information
06:31 EDTGOOGGoogle reaches preliminary agreement with Italian regulators, WSJ says
Subscribe for More Information
06:21 EDTAAPLFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
06:04 EDTAAPLApple to publicly beta test iOS update, Re/code says
Apple plans to allow consumers to test the next update for its iOS mobile operating system, reports Re/code. The beta test will be available mid-March through the company's Apple Seed program. Reference Link
05:29 EDTAAPLApple to invest EUR 1.6B in new European data centers
Subscribe for More Information
05:27 EDTAAPLApple to invest EUR 1.6B in new European data centers
February 22, 2015
17:11 EDTAAPLApple could reach $160 in a year, Barron's says
Subscribe for More Information
15:11 EDTAAPLApple increases capabilities in industrial lithium-ion batteries, Reuters says
Subscribe for More Information
February 20, 2015
16:48 EDTREGN, AAPLDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
16:03 EDTAAPLOptions Update; February 20, 2015
Subscribe for More Information
12:07 EDTREGNEYLEA reimbursment could be influenced by UK recommendation, says Piper Jaffray
Subscribe for More Information
12:02 EDTNVOEmisphere says Novo Nordisk completes Phase 2 OG217SC trial
Emisphere Technologies (EMIS) highlighted positive Phase 2 data from Eligen licensee Novo Nordisk (NVO) pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Results of the study are available on Novo Nordisk's website. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.
12:01 EDTREGNNICE recommends EYLEA for DME, but only in certain cases
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use